Author Archives: admin


Stem Cell Clinic > Articles by: admin

Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. – InvestorsObserver

By Stell Cell Research

Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. "Revolutionizing Regenerative Medicine: The Booming Frontier of Synthetic Stem Cells Unleashes Hope and Healing" PMI Leads the Way

Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- According to the recent research study, the Synthetic Stem Cells Market size was valued at about USD 8.9 Billion in 2024 and expected to grow at CAGR of 23.3% to extend a value of USD 60.1 Billion by 2034.

What is Synthetic Stem Cells?

Synthetic stem cells can be designed in laboratories by mimicking the properties of natural stem cells, such as their self-renewal capacity and pluripotency (ability to differentiate into multiple cell types). These artificial cells are often created using bioengineering techniques and may involve the use of biomaterials, genetic manipulation, or other advanced technologies. The field of synthetic stem cells holds promise for various medical applications, including regenerative medicine, tissue engineering, and disease treatment. By harnessing the potential of synthetic stem cells, researchers aim to develop innovative therapies for conditions such as injuries, degenerative diseases, and other disorders that involve damaged or malfunctioning tissues.

Driving Factors:

Restrain Factors:

Get Access to Free Sample Research Report with Latest Industry Insights:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3911

*Note: PMI Sample Report includes,

Report scope:

By Region - North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Top Leading Players in Synthetic Stem Cells Market:

Download PDF Brochure:

https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/3911

Emerging Trends and Opportunities in Synthetic Stem Cells Market:

Challenges of Synthetic Stem Cells Market:

Detailed Segmentation:

Key highlights of the Synthetic Stem Cells Market:

Any query or customization before buying:

https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/3911

Explore More Insights:

Blog: http://www.prophecyjournals.com

Follow us on:

LinkedIn | Twitter | Facebook | YouTube

See the article here:
Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. - InvestorsObserver

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

By Global News Feed

NAARDEN, the Netherlands and MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma and Ian Somaiya, chief financial officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 1:00 p.m. ET.

Visit link:
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK…

By Global News Feed

Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127

Read the original post:
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK...

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

By Global News Feed

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

More:
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

View original post here:
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revolution Medicines to Participate in Upcoming Investor Conferences

By Global News Feed

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.

Continue reading here:
Revolution Medicines to Participate in Upcoming Investor Conferences

Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

By Global News Feed

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:30 a.m. ET.

Continue reading here:
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

By Global News Feed

SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.

Go here to see the original:
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

By Global News Feed

HANOVER, MD, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces the closing of its previously announced public offering consisting of 1,555,555 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to 1,555,555 shares of its common stock, at a combined public offering price per share of common stock (or per pre-funded warrants in lieu thereof) and accompanying common warrant of $4.50. The closing occurred on January 30, 2024.

Read the rest here:
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

→←